Clinical research - Press Releases

Date	Title	Company
12-Dec-2019	Darzalex®▼ (daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Ineligible for Transplant	the Janssen Pharmaceutical Companies of Johnson & Johnson
12-Dec-2019	Darzalex®▼ (daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma	The Janssen Pharmaceutical Companies of Johnson & Johnson
12-Dec-2019	KITE, A GILEAD COMPANY, PRESENTS RESULTS FROM PIVOTAL ZUMA-2 TRIAL IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA	Kite, a Gilead Company
12-Dec-2019	PureTech Affiliate Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb's Opdivo® (Nivolumab)	Vedanta Biosciences
12-Dec-2019	Freeline appoints Julia P Gregory to its Board of Directors	Freeline
12-Dec-2019	Forendo Pharma Signs Important License and Collaboration Deal with Leading Pharma Company	Forendo Pharma
12-Dec-2019	Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors	Transgene
12-Dec-2019	Clevegen downregulates a range of major immuno-oncology (IO) checkpoints in MATINS cancer patients Biomarker analysis could guide future combination therapies with Clevegen	Faron Pharmaceuticals Oy
11-Dec-2019	Dr Samareh Lajaunias, Director at Combioxin Speaking at SMi's 22nd Annual Superbugs & Superdrugs Conference	SMi Group
11-Dec-2019	Invite from Lynne Ensor chair for Pharma Microbiology East Coast Conference, April 2020, Boston	SMi Group
11-Dec-2019	First NHS Trust Achieves Clinical Research Site Workforce Quality Accreditation	IAOCR
11-Dec-2019	Inceptua Appoints New CEO	Inceptua
10-Dec-2019	Stilla Technologies Names Key Leadership Slate to Support Global Growth of its Next-Generation Digital PCR Solution	Stilla Technologies
10-Dec-2019	Peregrine Ventures Raises $115 Million for its Fourth Fund Bringing Total Managed Funds and Co-Invest Capital to $400 Million	Peregrine
10-Dec-2019	Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion	Sanofi
10-Dec-2019	Vaccine Regimen from Janssen and Bavarian Nordic to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak	Bavarian Nordic
10-Dec-2019	bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition	bluebird bio, Inc
10-Dec-2019	Autolus Therapeutics Announces New Data Showcasing Clinical Progress of AUTO3 in B Cell Malignancies	Autolus Therapeutics plc
10-Dec-2019	KITE, A GILEAD COMPANY, ANNOUNCES LONG-TERM DATA FROM ZUMA-1 SHOWING 47% OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA PATIENTS WERE ALIVE THREE YEARS AFTER YESCARTA® (AXICABTAGENE CILOLEUCEL) TREATMENT	Kite, a Gilead Company
10-Dec-2019	Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers	Autolus Therapeutics plc